XML 22 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2019 $ 28,930 $ 80,169,724 $ (53,045,782) $ 27,152,872 $ 27,152,872
Balance (in Shares) at Sep. 30, 2019   28,930,493          
Issuance of common stock upon exercise of warrants $ 9,804 7,146,745 7,156,549 7,156,549
Issuance of common stock upon exercise of warrants (in Shares)   9,804,415          
Issuance of common stock for services $ 624 528,146 528,770 528,770
Issuance of common stock for services (in Shares)   623,740          
Issuance of common stock in registered direct offering, net of costs $ 7,059 6,870,041 6,877,100 6,877,100
Issuance of common stock in registered direct offering, net of costs (in Shares)   7,058,824          
Issuance of common stock in underwritten offering, net of costs $ 9,160 8,691,041 8,700,201 8,700,201
Issuance of common stock in underwritten offering, net of costs (in Shares)   9,159,524          
Stock-based compensation expense 803,261 803,261 803,261
Net loss (17,548,085) (17,548,085) (17,548,085)
Balance at Sep. 30, 2020 $ 55,577 104,208,958 (70,593,867) 33,670,668 33,670,668
Balance (in Shares) at Sep. 30, 2020   55,576,996          
Issuance of common stock upon exercise of warrants $ 23,996 31,106,138 31,130,134 31,130,134
Issuance of common stock upon exercise of warrants (in Shares)   23,995,907          
Issuance of common stock for services $ 50 67,950 68,000 68,000
Issuance of common stock for services (in Shares)   50,000          
Issuance of common stock upon exercise of stock options $ 70 82,564 82,634 82,634
Issuance of common stock upon exercise of stock options (in Shares)   70,000          
Issuance of NoveCite common stock 1,799,640 (2,399,520) (599,880) 600,380 500
Issuance of common stock in private placement offering, net of costs $ 15,456 18,434,954 18,450,410 18,450,410
Issuance of common stock in private placement offering, net of costs (in Shares)   15,455,960          
Issuance of common stock in registered direct offering, net of costs $ 50,830 70,929,012 70,979,842 70,979,842
Issuance of common stock in registered direct offering, net of costs (in Shares)   50,830,566          
Stock-based compensation expense 1,454,979 1,454,979 1,454,979
Net loss (23,054,434) (23,054,434) (23,054,434)
Balance at Sep. 30, 2021 $ 145,979 $ 228,084,195 $ (96,047,821) $ 132,182,353 $ 600,380 $ 132,782,733
Balance (in Shares) at Sep. 30, 2021   145,979,429